Cytokinetics, Incorporated
NASDAQ:CYTKBiotechnology
+$2.90 today
- Market cap
- $7.15B
- Beta
- 0.43
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$6.73
Volume 1.59M
Average 2.37M
CYTK Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Cytokinetics, IncorporatedNASDAQ: CYTK
Gross Margin · Q2 FY2026 · quarter ended Jun 2026
Gross margin narrows to 91.4%
Gross margin was 91.4% in Q2 FY2026, down 8.6 pp from a year earlier. On a trailing-twelve-month basis it was 88.7%, down 11.3 pp year over year. Over 3 fiscal years it widened by 243.1 pp.
Context
- Gross margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 88.5%
- Year-over-year change
- +1825.7pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 88.5% | +1825.7pp |
| FY2024 | 2024-12-31 | -1737.2% | +2546.9pp |
| FY2023 | 2023-12-31 | -4284.1% | -4129.5pp |
| FY2022 | 2022-12-31 | -154.6% | -27.5pp |
| FY2021 | 2021-12-31 | -127.1% | — |
Gross Margin vs competitors
How CYTK compares with its peers on the latest reported figures
- CYTK's LTM Jun 2026 gross margin of 88.7% is the lowest of the 3 companies compared; the peer median is 122.4%.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 144.9% | — | — | |
| FY2025 | 100.0% | — | — | |
| LTM Jun 2026 | 88.7% | -11.3 pp | +243.1 pp | |
| — | — | — | — | |
| Peer median (excluding CYTK) | 122.4% | — | — | |
Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 70.43M | 94.59M | 7.53M | 18.47M | 88.04M |
| Cost of Revenue | 159.94M | 240.81M | 330.12M | 339.41M | 10.13M |
| Gross Profit | (89.51M) | (146.23M) | (322.59M) | (320.93M) | 77.91M |
| Gross Margin | -127.1% | -154.6% | -4284.1% | -1737.2% | 88.5% |
| Research & Development | 159.94M | 240.81M | 330.12M | 339.41M | 405.9M |
| Selling, General & Admin | 96.8M | 177.98M | 173.61M | 215.31M | 284.27M |
| Operating Expenses | 96.8M | 177.98M | 173.61M | 215.31M | 690.17M |
| Depreciation & Amortization | 2.28M | 5.81M | 11.89M | 9.53M | 10.13M |
| EBITDA | (183.71M) | (331.99M) | (456.68M) | (493.48M) | (774.83M) |
| EBITDA Margin | -260.8% | -351.0% | -6064.9% | -2671.2% | -880.1% |
| Operating Income | (186.31M) | (324.2M) | (496.21M) | (536.25M) | (612.26M) |
| Operating Margin | -264.5% | -342.8% | -6589.7% | -2902.7% | -695.4% |
| Interest Income | 331K | 11.34M | 27.63M | 51.53M | 48.42M |
| Interest Expense | 29.33M | 51.16M | 57.67M | 86.51M | 103.87M |
| Other Income / Expenses | (29M) | (64.75M) | (30.04M) | (53.28M) | (172.7M) |
| Income Before Tax | (215.31M) | (388.96M) | (526.24M) | (589.53M) | (784.96M) |
| Pre-Tax Margin | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (215.31M) | (388.96M) | (526.24M) | (589.53M) | (784.96M) |
| Net Margin | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% |
| EPS (Basic) | (2.80) | (4.33) | (5.45) | (5.26) | (6.54) |
| EPS (Diluted) | (2.80) | (4.33) | (5.45) | (5.26) | (6.54) |
| Weighted Avg Shares | 76.89M | 89.83M | 96.52M | 111.98M | 120.02M |
| Weighted Avg Shares (Diluted) | 76.89M | 89.83M | 96.52M | 111.98M | 120.1M |
Cytokinetics, Incorporated
NASDAQ:CYTK
Intrinsic Alpha fair value
Locked
Current Price
$51.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.